Axelar AB Appoints Carl Harald Janson as CEO
News Oct 01, 2012
Axelar AB has announced the appointment of Carl Harald Janson as new CEO.
“We are very pleased to have appointed Carl Harald Janson as our new CEO in Axelar AB”, says Göran Pettersson, Chairman of Axelar.
Pettersson continued, “Carl Harald has previously been a Member of the Board of Axelar. His broad experience in pharmaceutical development will be of great benefit to the company. Johan Harmenberg, CEO of Axelar since 2007, will continue as Chief Medical Officer.”
“I am excited to lead the experienced team of Axelar and to continue the development of AXL1717. I look forward to take this potential novel cancer treatment to proof-of-concept”, says Carl Harald Janson.
Janson continued, “I am also very pleased that Johan Harmenberg will continue as Chief Medical Officer.”
Carl Harald Janson also serves as CEO of Karolinska Developments fully owned oncology group KDev Oncology AB which includes Akinion Pharmaceuticals AB and GliGene AB.
He previously worked as Vice President Portfolio Management at Karolinska Development from 2008 to 2011. He holds an MD and PhD from Karolinska Institutet and is a Certified European Financial Analyst (CEFA) from Stockholm School of Economics.
Carl Harald has over 25 years of experience in medicine, pharmaceutical development and asset management at Astra Arcus, Danske Securities and Carnegie Investment Bank.
He currently serves as Board Director of Clanotech AB and Akinion Pharmaceuticals AB.
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018